Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSRecruiting patients is one of the most challenging—and costly—aspects of rare disease research. It is estimated that about one-third of clinical trial failures overall may be due to enrollment challenges, and with rare disease research the obstacles are even greater.
Traditional methods for recruitment of patients are frequently not adequate to populate these trials. Small numbers of patients who are spread over large geographic areas, as well as singular aspects of specific diseases that may not be well understood make it difficult to find and recruit enough patients to meet enrollment goals. And as more companies pursue rare disease and precision medicine research, these recruiting challenges will only increase.
One way to mitigate these risks is by leveraging real-world data and innovations in advanced analytics and machine learning technology to develop more targeted recruiting strategies. Access to big data and advances in data analytics tools are enabling an information revolution in the biopharma industry. These analytics tools can be applied from early trial design and protocol planning through enrollment and study conduct to tailor the research process to the specific patient populations. We have already seen applications of these technologies result in dramatic improvements to identify hard-to-find patients.
However, there are hurdles to incorporating this data effectively. At DIA 2017 Annual Meeting in Chicago (June 18-24), I will participate in a session on rare disease recruiting and the use of big data with investigator and patient advocacy outreach to provide clarity on this topic. The session will explore unique recruiting strategies for rare disease research, and will share specific examples from a trial of Idiopathic Pulmonary Fibrosis patients to highlight how combining real world data and collaboration with patient groups in early planning stages, can improve trial design and accelerate patient recruitment.
Raw data on its own is only a resource, and requires expertise, context, and perspective to add value to any clinical research project. One common challenge in using data to inform trial design or recruiting is that a single database may not provide information that is consistent with the known disease landscape, or it can be biased, which may cloud decision-making. For example, patients in a specific community or healthcare system may be more likely to be prescribed a certain medication or to follow a unique treatment path that is not reflective of the broader patient population. In other cases, physician data may suggest a high percentage of patients are receiving a specific prescription however pharmacy data suggests they aren’t filling these prescriptions. Researchers may also fail to access the right sets of data if they don’t know what to look for. If they only use data from centers of excellence, for example, they may miss patients being treated by local physicians; or in relying on outdated data, they can make false assumptions about current standards of care.
To generate the most benefit from any of these data sets, research teams need to enhance them with insights from other trusted sources.
In the DIA session, I will discuss how database-derived information has been used in combination with feedback from physicians and patient groups to generate an improved understanding of the disease landscape in Idiopathic Pulmonary Fibrosis. By combining raw data with more ‘traditional’ sources, we were able to enrich the information and improve the context of the data, to the benefit of the trial and the patient community.
Integrating multiple data sources with ‘soft’ knowledge from patients and investigators can help researchers gain context from the data, and decide when and whether to expand the data search or modify the interpretation. It is this combination of information and expertise that brings the most value from big data to the clinical research process.